Trial Profile

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Necrobiosis lipoidica
Focus Therapeutic Use

Most Recent Events

01 Sep 2024 Results published in the Journal of Investigative Dermatology
21 Mar 2023 Results characterizing the effects of ruxolitinib in NL using transcriptomic analysis, presented at the American Academy of Dermatology annual Meeting 2023
17 Mar 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com